Table 2.
Incidence of tipifarnib toxicity stratified by cancer type
| Solid tumours | r-AML | Overall | ||
|---|---|---|---|---|
| Toxicity | Placebo, N (%) | Tipifarnib, N (%) | Tipifarnib, N (%) | Tipifarnib, N (%) |
| Non-haematological grade ≥ 2 | ||||
| AST | 25 (20.6) | 20 (7.6) | 15 (7.94) | 35 (7.7) |
| ALT | 18 (14.2) | 13 (4.7) | 21 (11.2) | 34 (7.3) |
| Bilirubin | 31 (24.4) | 41 (14.6) | 40 (21.3) | 81 (17.3) |
| Creatinine | 6 (4.7) | 20 (7.0) | 59 (11.3) | 79 (15.3) |
| Skin rash | 3 (2.6) | 29 (9.7) | 42 (17.4) | 71 (13.1) |
| CNS neuropathy | 30 (22.6) | 74 (24.8) | 69 (28.5) | 143 (26.5) |
| Peripheral neuropathy | 4 (3.0) | 23 (7.7) | 29 (12.0) | 52 (9.6) |
| Nausea and vomiting | 27 (20.3) | 61 (20.5) | 68 (28.1) | 129 (23.9) |
| Diarrhoea | 4 (3.0) | 33 (11.1) | 48 (19.8) | 81 (15.0) |
| GI inflammation | 4 (3.0) | 34 (11.4) | 54 (22.3) | 88 (16.3) |
| Haematological grade ≥ 3 | ||||
| Neutropenia | 1 (0.8) | 73 (24.9) | 196 (86.3) | – |
| Thrombocytopenia | 2 (1.5) | 44 (14.7) | 224 (94.9) | – |